PEBP1 and Familial prostate cancer: However, western blotting analysis confirmed the trend toward a significant reduction of urinary RKIP previously observed in the SELDI experiments and the potential utility of this biomarker to distinguish ccRCC patients from HS and prostatic cancer (Figure 3).